Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSCINASDAQ:CYCNNASDAQ:PHIONASDAQ:QLGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSCICOSCIENS Biopharma$3.55+13.4%$2.96$1.96▼$6.77$11.15M1.2713,254 shs9,633 shsCYCNCyclerion Therapeutics$3.35-9.5%$2.68$1.27▼$9.47$9.08M1.961.31 million shs20,804 shsPHIOPhio Pharmaceuticals$1.98-7.5%$1.59$0.97▼$9.79$9.46M1.092.32 million shs240,929 shsQLGNQualigen Therapeutics$3.59+2.3%$3.28$2.85▼$29.44$2.64M0.2112,456 shs4,773 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSCICOSCIENS Biopharma+0.47%+6.07%+5.34%+17.00%+323,499,900.00%CYCNCyclerion Therapeutics+13.85%+37.04%+43.97%+51.02%+26.28%PHIOPhio Pharmaceuticals+4.90%-24.38%+65.89%-16.08%-65.14%QLGNQualigen Therapeutics+1.15%-0.57%-7.63%+12.50%-75.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACYCNCyclerion Therapeutics1.8619 of 5 stars0.03.00.00.03.83.30.6PHIOPhio Pharmaceuticals2.5841 of 5 stars3.52.00.00.03.20.81.3QLGNQualigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSCICOSCIENS Biopharma 0.00N/AN/AN/ACYCNCyclerion Therapeutics 0.00N/AN/AN/APHIOPhio Pharmaceuticals 3.00Buy$4.00102.02% UpsideQLGNQualigen Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QLGN, PHIO, CSCI, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.002/19/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSCICOSCIENS Biopharma$9.59M1.16N/AN/A$14.99 per share0.24CYCNCyclerion Therapeutics$2M4.54N/AN/A$4.62 per share0.73PHIOPhio PharmaceuticalsN/AN/AN/AN/A$18.57 per shareN/AQLGNQualigen Therapeutics$4.98M0.53N/AN/A($20.31) per share-0.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSCICOSCIENS Biopharma-$16.55M-$9.38N/A∞N/A-428.43%-95.93%-45.66%5/13/2025 (Estimated)CYCNCyclerion Therapeutics-$5.26M-$1.22N/A∞N/AN/A-55.32%-48.35%5/5/2025 (Estimated)PHIOPhio Pharmaceuticals-$10.83M-$10.92N/A0.53N/AN/A-134.57%-108.39%5/8/2025 (Estimated)QLGNQualigen Therapeutics-$13.42MN/A0.00∞N/AN/AN/A-424.18%4/29/2025 (Estimated)Latest QLGN, PHIO, CSCI, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025N/APHIOPhio Pharmaceuticals-$1.23N/AN/AN/AN/AN/A4/9/2025Q4 2024CSCICOSCIENS Biopharma-$3.48-$2.15+$1.33-$2.15$1.10 million$3.32 million3/4/2025Q4 2024CYCNCyclerion TherapeuticsN/A$0.22N/A$0.22N/A$1.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSCICOSCIENS BiopharmaN/A3.463.05CYCNCyclerion TherapeuticsN/A5.075.07PHIOPhio PharmaceuticalsN/A6.386.38QLGNQualigen TherapeuticsN/A0.520.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSCICOSCIENS Biopharma0.73%CYCNCyclerion Therapeutics75.62%PHIOPhio Pharmaceuticals57.31%QLGNQualigen Therapeutics3.18%Insider OwnershipCompanyInsider OwnershipCSCICOSCIENS Biopharma0.10%CYCNCyclerion Therapeutics36.10%PHIOPhio Pharmaceuticals0.59%QLGNQualigen Therapeutics1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSCICOSCIENS Biopharma203.14 million3.77 millionN/ACYCNCyclerion Therapeutics302.71 million1.73 millionNo DataPHIOPhio Pharmaceuticals104.78 million6.85 millionNot OptionableQLGNQualigen Therapeutics50736,000723,000Not OptionableQLGN, PHIO, CSCI, and CYCN HeadlinesRecent News About These CompaniesQualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire MarizymeApril 1, 2025 | finance.yahoo.comQualigen Therapeutics Delays Yearly Financial ReportApril 1, 2025 | tipranks.comQualigen Therapeutics to participate in next funding round for NanoSynexJanuary 28, 2025 | markets.businessinsider.comQualigen to invest in NanoSynex, stock tumbles 21%January 28, 2025 | msn.comQualigen to participate in next funding round for NanoSynexJanuary 28, 2025 | markets.businessinsider.comQualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity RequirementDecember 6, 2024 | markets.businessinsider.comQualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price and Equity RequirementsDecember 5, 2024 | quiverquant.comUnivest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)November 25, 2024 | globenewswire.comQualigen Therapeutics secures $4.5 million in fundingNovember 21, 2024 | investing.comQualigen announces $4.5M private placement of Preferred SharesNovember 20, 2024 | markets.businessinsider.comQualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred SharesNovember 20, 2024 | finance.yahoo.comQualigen Therapeutics, Inc. Secures $4.5 Million in Preferred Shares OfferingNovember 19, 2024 | quiverquant.comQualigen Therapeutics Appoints Graydon Bensler to BoardNovember 15, 2024 | markets.businessinsider.comQualigen Therapeutics trading halted, news pendingNovember 5, 2024 | markets.businessinsider.comQualigen Therapeutics Inc (QLGN) Reported a 0.00% Operating Margin Last Year—What’s the Real Story?November 5, 2024 | bovnews.comQualigen Therapeutics Announces 1-for-50 Reverse Stock SplitNovember 1, 2024 | markets.businessinsider.comQLGN’s Recent Drop: What’s Causing the Decline?November 1, 2024 | bovnews.comShares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024November 1, 2024 | globenewswire.comThe QLGN Conundrum: Why Qualigen Therapeutics Inc’s Stock Is Making Headlines AgainOctober 28, 2024 | bovnews.comWhat’s Causing Qualigen Therapeutics Inc (QLGN) Stock’s -43.67% Drop Over the Last Six Months?October 25, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQLGN, PHIO, CSCI, and CYCN Company DescriptionsCOSCIENS Biopharma NASDAQ:CSCI$3.55 +0.42 (+13.42%) Closing price 03:42 PM EasternExtended Trading$3.63 +0.08 (+2.25%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Cyclerion Therapeutics NASDAQ:CYCN$3.35 -0.35 (-9.46%) Closing price 04:00 PM EasternExtended Trading$3.40 +0.04 (+1.34%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Phio Pharmaceuticals NASDAQ:PHIO$1.98 -0.16 (-7.48%) Closing price 04:00 PM EasternExtended Trading$2.02 +0.04 (+1.97%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.Qualigen Therapeutics NASDAQ:QLGN$3.59 +0.08 (+2.25%) Closing price 03:58 PM EasternExtended Trading$3.59 +0.00 (+0.03%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
